Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 3 spellings of its name, each linked to the record.
As of Nov 22, 2026, FDA's public records list Fidelity BioPharma with 1 complete response letter, 1 510(k) clearance and 1 drug application. The most recent is a 510(k) clearance dated Sep 6, 2026: KCS rTMS Therapy System (Transcranial Magnetic Stimulator) (MetaStim 100, MetaStim 100A).
Drug approvals, 510(k) clearances, recalls and letters, 2024 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Sep 6, 2026 | KCS rTMS Therapy System (Transcranial Magnetic Stimulator) (MetaStim 100, MetaStim 100A)K260396 · OBP | 510(k) clearance |
| Dec 12, 2024 | OntralfyNDA 216190 | Drug application |
| Mar 29, 2024 | Complete response letter, NDA 216190Approved | Complete response letter |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.